Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. (2023)
Attributed to:
AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s1473-3099(22)00644-2
PubMed Identifier: 36272432
Publication URI: http://europepmc.org/abstract/MED/36272432
Type: Journal Article/Review
Volume: 23
Parent Publication: The Lancet. Infectious diseases
Issue: 2
ISSN: 1473-3099